FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Gold Prices Dip Slightly But Hold Weekly Gains Amid U.S.-Iran Ceasefire Hopes 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
IMF Warns Middle East War to Deepen Economic Divide Across Latin America and Caribbean 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Asian Currencies Rally as Dollar Weakens Amid Iran Ceasefire Hopes 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Energy Price Spike Won't Trigger Lasting Inflation, Analysts Say 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
SK Biopharmaceuticals, the South Korean pharmaceutical giant, projects $1 billion in U.S. sales by 2029 for its flagship anti-epilepsy treatment, Xcopri. The firm, combating a sales decline in 2020, hopes this drug will bolster its financial turnaround, positioning it as a global biotech leader.
Xcopri, or cenobamate, is a medication developed by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science for treating partial-onset seizures in adults. It was approved for medical use in the U.S. at the end of 2019 and in Europe in 2021. In Europe, it is marketed under the brand name Ontozry.
The total prescriptions (TRx) for Xcopri, a key metric used in the pharmaceutical industry to measure a medicine's launch performance, have reached 22,000 monthly in the U.S. market this year. This number is projected to grow to 30,000 per month next year, establishing Xcopri as a leading anti-epilepsy treatment in the U.S. Lee Dong-hoon, CEO of SK Biopharmaceuticals, said they anticipate U.S. sales for Xcopri to break even by the end of this year and to reach $1 billion by 2029 and skyrocket to $3.5 billion by 2032.
In 2020, SK Biopharmaceuticals reported a significant decline of 50.8% in sales, amounting to 456.7 billion won ($362 million). However, Xcopri, with a gross profit margin of 90%, is expected to contribute to the company's financial growth.
The CEO emphasized the valuable stability that Xcopri will bring to the company's future revenue streams, allowing for an expansion of SK Biopharmaceuticals' business portfolio to become a global biotech platform company.
Lee stated that the company would enhance its therapeutic modalities, focusing on radiopharmaceutical therapy (RPT), a groundbreaking approach that delivers radiation therapy directly to cancer cells. SK Biopharmaceuticals aims to secure rights for radioisotope supply, which is crucial for RPT medications, through collaboration with TerraPower, a U.S. venture founded by Bill Gates that specializes in small-sized nuclear power reactors. Lee highlighted the significance of the cell and gene therapy sector as another key area of focus for SK Biopharmaceuticals moving forward.
In addition, SK Biopharmaceuticals will strengthen its targeted protein degradation (TPD) platform. This effort follows the recent acquisition of Proteovant Therapeutics, a U.S. biotech company with advanced TPD technology that can effectively target disease-causing proteins.
As the company expands its capabilities and ventures into new territories, it aims to position itself as a global biotech leader with a unique business model, transitioning from a single asset-based company to a comprehensive powerhouse.
Photo: Hal Gatewood/Unsplash
